Company profile for ERS Genomics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

ERS Genomics was formed to commercialise the foundational CRISPR-Cas9 intellectual property held by co-inventor, co-owner and Nobel Prize-winner Dr. Emmanuelle Charpentier. Licenses are available in multiple fields of use. CRISPR-Cas9 is a revolutionary new genome editing technology, which offers significant advantages in speed, efficiency and cost over earlier genome editing methods. Our team has decades of experience in ...
ERS Genomics was formed to commercialise the foundational CRISPR-Cas9 intellectual property held by co-inventor, co-owner and Nobel Prize-winner Dr. Emmanuelle Charpentier. Licenses are available in multiple fields of use. CRISPR-Cas9 is a revolutionary new genome editing technology, which offers significant advantages in speed, efficiency and cost over earlier genome editing methods. Our team has decades of experience in the field of genome editing and its application, in business development and licensing, licensing preclinical and clinical stage therapeutic products and drug delivery technologies, genome editing technologies.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Ireland
Address
Address
8th Floor, Block E, Iveagh Court, Harcourt Road, Dublin D02 YT22, Ireland
Telephone
Telephone
+353 (0)1 539-0082
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/ers-genomics-and-dyadic-applied-biosolutions-sign-crisprcas9-license-agreement-302610320.html

PR NEWSWIRE
10 Nov 2025

https://www.globenewswire.com/news-release/2025/01/13/3008603/0/en/ERS-Genomics-launches-Express-License-platform-to-democratise-access-to-CRISPR-Cas9.html

GLOBENEWSWIRE
13 Jan 2025

https://www.businesswire.com/news/home/20240904321742/en

BUSINESSWIRE
04 Sep 2024

https://www.businesswire.com/news/home/20240520044085/en

BUSINESSWIRE
20 May 2024

https://www.businesswire.com/news/home/20240513334659/en

BUSINESSWIRE
13 May 2024

https://www.prnewswire.com/news-releases/ers-genomics--demeetra-enter-into-crisprcas9-licensing-agreement-301930759.html

PR NEWSWIRE
18 Sep 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty